Fulcrum Therapeutics Gestion
Gestion contrôle des critères 2/4
Le PDG Fulcrum Therapeutics est Alex Sapir, nommé en Jul2023, a un mandat de 3.08 ans. La rémunération annuelle totale est $ 3.25M, composée du salaire de 20% et des bonus 80%, y compris les actions et options de la société. détient directement 0.26% des actions de la société, d'une valeur de $ 745.42K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3 ans et 8.2 ans.
Informations clés
Alex Sapir
Directeur général
US$3.3m
Rémunération totale
| Pourcentage du salaire du PDG | 19.99% |
| Durée du mandat du directeur général | 3.1yrs |
| Propriété du PDG | 0.3% |
| Durée moyenne d'occupation des postes de direction | 3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 8.2yrs |
Mises à jour récentes de la gestion
Recent updates
FULC: Cash-Rich Balance Sheet Will Underpin Post-Program Strategic Review Outcomes
Analysts have reset expectations on Fulcrum Therapeutics, with price targets now clustered in the $3 to $4 range. This reflects the removal of pociredir from models and a focus on the company’s cash position and ongoing review of options.Fulcrum Therapeutics: Buy It For The Strategic Reset
Summary Fulcrum is trading at a deep discount due to operational distress after the suspension of their main program. But because of their fortress balance sheet, Fulcrum should have the financial strength to reset. Fulcrum is a financially strong company in operational distress, and it's trading below NCAV, making it comparable to issues that have strongly outperformed the market. Read the full article on Seeking Alpha
FULC: Cash Review And Restructuring Will Drive Future Share Repricing
Fulcrum Therapeutics' analyst fair value estimate has been revised from $25.00 to about $16.75 as analysts factor in widespread rating downgrades and sharply reduced price targets, following the discontinuation of the pociredir program in sickle cell disease and the shift toward a cash-focused review of options. Analyst Commentary Recent research on Fulcrum Therapeutics points to a broad reset in expectations after the discontinuation of pociredir in sickle cell disease, with multiple firms revising ratings and price targets, and several explicitly framing the stock more as a cash-focused situation during the current review of options.FULC: Cash-Rich Balance Sheet Will Shape Post-Program Review Outcome
The updated analyst price target for Fulcrum Therapeutics has shifted sharply lower, with the fair value estimate moving from about $19.00 to roughly $5.43. Analysts are factoring in the discontinuation of pociredir in sickle cell disease, class-wide safety concerns around PRC2 inhibitors, and the company's transition into a cash-focused story undergoing a review of alternatives.Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. By way of example, Fulcrum...Fetal Hemoglobin Induction Will Reshape Sickle Cell Care And Broaden Long Term Hematology Potential
Catalysts About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical stage biopharmaceutical company focused on small molecule treatments for genetically defined diseases, with an emphasis on sickle cell disease and hematologic conditions. What are the underlying business or industry changes driving this perspective?Oral Fetal Hemoglobin Induction Will Reshape Severe Sickle Cell Treatment Over The Long Term
Catalysts About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical stage biopharmaceutical company focused on developing oral fetal hemoglobin inducers for sickle cell disease and other hemoglobinopathies. What are the underlying business or industry changes driving this perspective?We're Not Very Worried About Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Fulcrum Therapeutics...Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Business And Shares Still Trailing The Industry
You may think that with a price-to-sales (or "P/S") ratio of 1.7x Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) is a stock...There's Reason For Concern Over Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Massive 34% Price Jump
Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders have had their patience rewarded with a 34% share price jump in...We Think Fulcrum Therapeutics (NASDAQ:FULC) Can Easily Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%
Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders that were waiting for something to happen have been dealt a...Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly
Summary Fulcrum Therapeutics, Inc.'s stock plummeted over 60% after its lead candidate, losmapimod, failed to meet primary and secondary endpoints in a Phase 3 study for FSHD. Despite prior optimism and significant investments from Sanofi and positive analyst ratings, the REACH trial's results were disappointing, leading to the suspension of the losmapimod program. Fulcrum's management, facing leadership changes and a challenging market, will now focus on its other clinical-stage candidate, pociredir, for sickle cell disease. With a market cap of $550m and nearly $300m in cash, the future value of Fulcrum's pipeline remains uncertain amidst intense competition. Read the full article on Seeking AlphaWill Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Fulcrum...Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today
The latest analyst coverage could presage a bad day for Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ), with the analysts...We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts
Today is shaping up negative for Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders, with the analysts delivering...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$85m |
| Mar 31 2026 | n/a | n/a | -US$76m |
| Dec 31 2025 | US$3m | US$650k | -US$75m |
| Sep 30 2025 | n/a | n/a | -US$71m |
| Jun 30 2025 | n/a | n/a | -US$73m |
| Mar 31 2025 | n/a | n/a | -US$510k |
| Dec 31 2024 | US$1m | US$650k | -US$10m |
| Sep 30 2024 | n/a | n/a | -US$18m |
| Jun 30 2024 | n/a | n/a | -US$20m |
| Mar 31 2024 | n/a | n/a | -US$99m |
| Dec 31 2023 | US$7m | US$369k | -US$97m |
Rémunération vs marché: La rémunération totale de Alex ($USD 3.25M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 1.63M ).
Rémunération et revenus: La rémunération de Alex a augmenté alors que l'entreprise n'est pas rentable.
PDG
Alex Sapir (59 yo)
Mr. Alexander C. Sapir, also known as Alex, serves as Chief Executive Officer, President and Director at Fulcrum Therapeutics, Inc. since July 01, 2023. Mr. Sapir has been Director at PhaseBio Pharmaceutic...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | 3.1yrs | US$3.25m | 0.26% $ 745.4k | |
| Chief Financial Officer | 3yrs | US$1.81m | 0% $ 0 | |
| Chief Legal Officer | 5.8yrs | US$1.48m | 0.013% $ 38.0k | |
| Founder | no data | pas de données | pas de données | |
| Founder | no data | pas de données | pas de données | |
| Founder | no data | pas de données | pas de données | |
| Founder | no data | pas de données | pas de données | |
| Founder | no data | pas de données | pas de données | |
| Senior Vice President of Early Development | 3.4yrs | pas de données | pas de données | |
| Head of Program Strategy & Vice President | 1.2yrs | pas de données | pas de données | |
| Chief Regulatory & Quality Assurance Officer | less than a year | pas de données | pas de données |
Gestion expérimentée: L'équipe de direction de FULC est considérée comme expérimentée (ancienneté moyenne 3 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | 3.1yrs | US$3.25m | 0.26% $ 745.4k | |
| Independent Director | 10.1yrs | US$274.91k | 0.12% $ 336.6k | |
| Independent Director | 1.8yrs | US$265.77k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Independent Director | 6.6yrs | US$279.41k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Director | 10.1yrs | US$269.41k | 0.60% $ 1.7m | |
| Independent Director | 9.7yrs | US$273.05k | 0.014% $ 40.5k | |
| Independent Chair of the Board | 8.2yrs | US$300.91k | 0% $ 0 | |
| Member of FSHD Clinical Advisory Board | no data | pas de données | pas de données | |
| Member of FSHD Clinical Advisory Board | no data | pas de données | pas de données | |
| Member of FSHD Clinical Advisory Board | no data | pas de données | pas de données |
Conseil d'administration expérimenté: Les membres du conseil d'administration de FULC sont considérés comme expérimentés (ancienneté moyenne 8.2 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/04 09:41 |
| Cours de l'action en fin de journée | 2026/08/03 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Fulcrum Therapeutics, Inc. est couverte par 16 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |
| Kristen Kluska | Cantor Fitzgerald & Co. |